RxDoctor Payments Data

Paul Miller, MD

Internal Medicine · Catonsville, MDNPI 1861489197

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.5% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 54.7% of the total. Reporting peaked in 2023 at $152 and has fallen 68.8% since, to $47 in 2025.

$289in general payments, 2019–2025

Across 13 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$158
  • Abbott$48
  • AbbVie$32
  • Boehringer Ingelheim$19
  • Sanofi Pasteur Inc.$18
  • Tactile Systems Technology Inc$15
$15,630in research payments, 2019–2025

Across 2 payments — averaging $7815.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$16K

What the payments were for

  • Food & beverage$27093%
  • Education$197%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$289 in reported general payments places this provider in the 55th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland →

Medicare billing

Part B allowed, 2024
$176,340
Medicare patients
363
Services billed
2,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$62,170
RybelsusSemaglutide15$37,742
XareltoRivaroxaban21$27,962
JardianceEmpagliflozin13$21,983
JanuviaSitagliptin Phosphate14$16,634
OzempicSemaglutide11$14,951
Opium Tincture11$12,923
FarxigaDapagliflozin Propanediol11$11,359
Atorvastatin Calcium473$7,570
Spiriva RespimatTiotropium Bromide12$6,078
Gabapentin140$3,173
Pravastatin Sodium122$2,832
Losartan Potassium198$2,690
Rosuvastatin Calcium73$2,356
Lisinopril237$2,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$19$28,06025 claims
MerckJanuvia$158$16,63414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Catonsville

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →